Solabegron - Velicept Therapeutics
Alternative Names: 427353; GW-427353; GW-427353B; Solabegron; Solabegron hydrochlorideLatest Information Update: 29 Nov 2022
At a glance
- Originator GlaxoSmithKline
- Developer AltheRx; Velicept Therapeutics
- Class Aniline compounds; Antihyperglycaemics; Benzoic acids; Obesity therapies; Small molecules
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Irritable bowel syndrome; Overactive bladder
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 29 Nov 2022 No development reported - Phase-II for Overactive bladder in USA (PO) (Controlled release)
- 28 Jul 2019 No recent reports of development identified for preclinical development in Overactive bladder(Combination therapy) in USA (PO)
- 02 May 2019 Velicept Therapeutics completes a phase II trial in Overactive bladder in USA (PO) in USA (NCT03594058)